Clinical trials in San Donato Milanese – page 91

2 835 clinical trials in San Donato Milanese, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

San Donato Milanese at a glance

2 835

clinical trials

Research sites1

Quick filters

2 835 trials in San Donato Milanese

Open in trial search

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

Investigational

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

Investigational

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Rezpegaldesleukin
Sponsor:Nektar Therapeutics

Contact Research Centre

Ovarian cancer

Not yet recruiting

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Pruritus

Not yet recruiting

Efficacy and safety of remibrutinib, tacrolimus and pimecrolimus in adults with severe chronic pruritus of unknown origin: a randomized, placebo‑controlled trial

Registered drug

Efficacy and safety of remibrutinib, tacrolimus and pimecrolimus in adults with severe chronic pruritus of unknown origin: a randomized, placebo‑controlled trial

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Pimecrolimus
Sponsor:Novartis Pharma AG

Contact Research Centre

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anifrolumab
Sponsor:AstraZeneca AB

Contact Research Centre

Small cell lung cancer+2

Not yet recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:BioNTech SE

Contact Research Centre

Colorectal cancer metastatic

Not yet recruiting

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Genmab A/S

Contact Research Centre

Cardiovascular disorder+3

Not yet recruiting

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational

Italy

Participants:18–64 years
Substances:LY3841136 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Hypersomnia

Not yet recruiting

Phase 3 Randomized Double‑Blind Study of Pitolisant versus Placebo for Safety and Efficacy in Adults with Idiopathic Hypersomnia

Investigational

Phase 3 Randomized Double‑Blind Study of Pitolisant versus Placebo for Safety and Efficacy in Adults with Idiopathic Hypersomnia

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Pitolisant
Sponsor:Harmony Biosciences Management Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Not yet recruiting

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:EXPD-101
Sponsor:Expedition Therapeutics Inc.

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:REGN9933
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Pituitary-dependent Cushing's syndrome

Not yet recruiting

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Atumelnant
Sponsor:Crinetics Pharmaceuticals Inc.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in San Donato Milanese

What the registry says about research in the country

01 Gastroenterology Research

Leading studies focusing on inflammatory bowel diseases, including investigations of novel treatments for Crohn's Disease and Ulcerative Colitis. Research encompasses both established and experimental therapies aimed at inducing clinical remission.

Crohn's Disease Management
Ulcerative Colitis Treatments
Fecal Incontinence Therapy

Multiple trials evaluating innovative therapeutic approaches for gastrointestinal conditions.

02 Cardiovascular Studies

Comprehensive research into heart conditions, with particular emphasis on hypertrophic cardiomyopathy and heart failure. Studies evaluate new medications and surgical interventions.

Heart Failure Management
Cardiac Surgery Outcomes
Myocardial Infarction Research

Innovative approaches in treating various cardiac conditions using precision medicine techniques.

03 Immunology Research

Groundbreaking studies in hereditary angioedema and chronic urticaria, investigating both preventive treatments and acute attack management strategies.

Hereditary Angioedema Treatments
Chronic Urticaria Management
Pediatric Immunology Studies

Advanced therapeutic options being developed for rare immunological disorders.

Back to Italy All countries